A BILL 
To require the Secretary of Health and Human Services 
to establish an annual reference price for insulin prod-
ucts for purposes of Federal health programs, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘End Price Gouging 
4
for Insulin Act’’. 
5
18:35 Dec 12, 2019
H5364
2 
•HR 5364 IH
SEC. 2. REFERENCE PRICE FOR INSULIN PRODUCTS. 
1
(a) REFERENCE PRICE.—The Secretary of Health 
2
and Human Services (referred to in this section as the 
3
‘‘Secretary’’), in accordance with subsection (b), shall es-
4
tablish an annual reference price for insulin products. 
5
Notwithstanding any other provision of law, including sec-
6
tion 1860D–11(i) of the Social Security Act (42 U.S.C. 
7
1395w–111(i)), with respect to enrollees or beneficiaries 
8
in any of the Federal health programs described in sub-
9
section (c), the wholesale acquisition cost for insulin prod-
10
ucts, including the cost-sharing amount, shall not exceed 
11
the reference price for the applicable year. 
12
(b) CRITERIA.— 
13
(1) IN
GENERAL.—Not later than 6 months 
14
after the date of enactment of this Act and every 6 
15
months thereafter, the Secretary shall establish the 
16
reference price for insulin products— 
17
(A) by determining the median wholesale 
18
acquisition cost or the commensurate list price 
19
in the reference countries for insulin products 
20
among the reference countries in which such 
21
products are available, if insulin product pricing 
22
information is available for at least three of 
23
such countries; or 
24
(B) in the case that insulin product pricing 
25
information or dosage equivalents are not avail-
26
18:35 Dec 12, 2019
H5364
3 
•HR 5364 IH
able for at least three of the reference coun-
1
tries, by determining an appropriate price based 
2
on— 
3
(i) the clinical and therapeutic effect 
4
and value of the product; 
5
(ii) patient access to the product; 
6
(iii) the costs associated with manu-
7
facturing, marketing, researching, and de-
8
veloping the product; 
9
(iv) total revenues, net profit, and ex-
10
ecutive compensation associated with the 
11
manufacturer of the product; and 
12
(v) other factors, as the Secretary de-
13
termines appropriate. 
14
(2) REFERENCE COUNTRIES.—For purposes of 
15
paragraph (1), the reference countries are Japan, 
16
Germany, the United Kingdom, France, Italy, Can-
17
ada, Australia, Spain, the Netherlands, Switzerland, 
18
and Sweden. 
19
(c) FEDERAL HEALTH PROGRAMS.—The reference 
20
price established under subsection (a) shall apply with re-
21
spect to covered insulin products under— 
22
(1) the Medicare program under title XVIII of 
23
the Social Security Act (42 U.S.C. 1395 et seq.); 
24
18:35 Dec 12, 2019
H5364
4 
•HR 5364 IH
(2) a State Medicaid plan under title XIX of 
1
the Social Security Act (42 U.S.C. 1396 et seq.); 
2
(3) the State Children’s Health Insurance Pro-
3
gram under title XXI of the Social Security Act (42 
4
U.S.C. 1397aa et seq.); 
5
(4) the TRICARE program under chapter 55 of 
6
title 10, United States Code; 
7
(5) hospital care and medical services furnished 
8
by the Department of Veterans Affairs under chap-
9
ters 17 and 18 of title 38, United States Code; 
10
(6) the Federal Employees Health Benefits 
11
Program established under chapter 89 of title 5, 
12
United States Code; and 
13
(7) any health program, service, function, activ-
14
ity, or facility funded, in whole or part, under the 
15
Indian Health Care Improvement Act (25 U.S.C. 
16
1601 et seq.), including through direct or contract 
17
care provided under such Act or through a contract 
18
or compact under the Indian Self-Determination and 
19
Education Assistance Act (25 U.S.C. 5304 et seq.). 
20
(d) APPLICABILITY TO OTHER PURCHASERS OF IN-
21
SULIN PRODUCTS.—Notwithstanding any other provision 
22
of law, an insulin product manufacturer shall offer such 
23
product at the reference price to all individuals, including 
24
individuals who are not insured and individuals who are 
25
18:35 Dec 12, 2019
H5364
5 
•HR 5364 IH
covered under a group health plan or group or individual 
1
health insurance coverage. 
2
(e) CIVIL PENALTY.—The Secretary shall enforce 
3
this section by imposing a civil penalty upon any insulin 
4
product manufacturer who does not comply with the re-
5
quirements of subsection (a), for each year in which the 
6
violation occurs, in an amount equal to 10 times the dif-
7
ference between— 
8
(1) the total amount received by the manufac-
9
turer for sales of insulin products under the Federal 
10
health programs under subsection (c) for the year; 
11
less 
12
(2) the total amount the manufacturer would 
13
have received for sales of insulin products under 
14
such programs for the year if the manufacturer had 
15
complied with subsection (a). 
16
(f) USE OF AMOUNTS COLLECTED.—Each year, the 
17
Secretary of the Treasury shall allocate the amount col-
18
lected under subsection (e) for the previous year as fol-
19
lows: 
20
(1) Half of such amount shall be deposited in 
21
the Federal Hospital Insurance Trust Fund and the 
22
Federal Supplementary Medical Insurance Trust 
23
Fund (including the Medicare Prescription Drug Ac-
24
count within such Trust Fund) in such proportion 
25
18:35 Dec 12, 2019
H5364
6 
•HR 5364 IH
as the Secretary of Health and Human Services de-
1
termines appropriate. 
2
(2) Half of such amount shall be transferred to 
3
the National Institutes of Health, for purposes of 
4
carrying out drug research and development. 
5
(g) APPLICABILITY TO BRAND AND GENERIC INSU-
6
LIN PRODUCTS.—The reference price established under 
7
subsection (a) shall apply to insulin products approved 
8
under subsection (c) or (j) of section 505 of the Federal 
9
Food, Drug, and Cosmetic Act (21 U.S.C. 355) or under 
10
subsection (a) or (k) of section 351 of the Public Health 
11
Service Act (42 U.S.C. 262). 
12
Æ 
18:35 Dec 12, 2019
H5364
